Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance
Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Marie‐Claude Hofmann(The University of Texas MD Anderson Cancer Center), Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Priyanka Iyer(The University of Texas MD Anderson Cancer Center)
Cited by 49
Related Papers
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|392
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
|Journal of Clinical Oncology|2012|231